Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study

Andres Forero-Torres, MD, Beata Holkova, MD, Jeff P. Sharman, MD, Jonathan W. Friedberg, MD, Maurice J. Berkowitz, MD, William Fintel, MD, Robert Chen, MD, Ralph V. Boccia, MD, Mansoor Saleh, MD, Neil Josephson, MD, Maria Corinna Palanca-Wessels, MD PhD, Christopher A. Yasenchak, MD

Blood (2014) 124 (21): 294.

https://doi.org/10.1182/blood.V124.21.294.294

Published: 2014

Journal Articles

Analysis of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind, Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth Factor.

James B. Bussel, MD, Gregory Cheng, MD, Mansoor Saleh, MD, Lidia Kovaleva, MD, Nicole Stone, PhD, Bhabita Mayer, MS, Julian Jenkins, MS, Andrew Provan, BSc, MBChB, MD

Blood (2006) 108 (11): 475.

https://doi.org/10.1182/blood.V108.11.475.475

Published: 2006

Journal Articles

Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma (NHL): A Phase 2 Study.

Sven de Vos, Shaker Dakhil, Peter McLaughlin, Mansoor Saleh, Robert Belt, Christopher Flowers, Mark Knapp, Lowell Hart, Dipti Patel-Donnelly, Martha Glenn, Stephanie A. Gregory, Charles Holladay, Anthony Boral, Tracy Zhang, André Goy

Blood (2005) 106 (11): 17.

https://doi.org/10.1182/blood.V106.11.17.17

Published: 2005

Journal Articles

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial

Gregory A. Wiseman, Leo I. Gordon, Pratik S. Multani, Thomas E. Witzig, Stewart Spies, Nancy L. Bartlett, Russell J. Schilder, James L. Murray, Mansoor Saleh, Roberta S. Allen, Antonio J. Grillo-López, Christine A. White

Blood (2002) 99 (12): 4336–4342.

https://doi.org/10.1182/blood.V99.12.4336

Published: 2002

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study

Analysis of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind, Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth Factor.

Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma (NHL): A Phase 2 Study.

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study

Analysis of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind, Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth Factor.

Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma (NHL): A Phase 2 Study.

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only